We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Ariceum Therapeutics Stock

Invest in or calculate the value of your shares in Ariceum Therapeutics or other pre-IPO companies through EquityZen's platform.

Get Started

Ariceum Therapeutics Stock (ARTH)

Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.

About Ariceum Therapeutics Stock

Founded

2021

Industries

Software, Artificial Intelligence, Data and Analytics

Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers. 177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, is an antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.

Ariceum Therapeutics Management

Leadership team at Ariceum Therapeutics

Board of Directors

Christoph Massner

Board Member

Per Samuelsson

Locked Features

Join now and verify your accreditation status to gain access to:

  • Ariceum Therapeutics current valuation
  • Ariceum Therapeutics stock price
  • Available deals in Ariceum Therapeutics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Ariceum Therapeutics stock?

Accredited investors can buy pre-IPO stock in companies like Ariceum Therapeutics through EquityZen funds. These investments are made available by existing Ariceum Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Ariceum Therapeutics stock?

Shareholders can sell their Ariceum Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."